Vera Long Term Debt To Capitalization from 2010 to 2024
| VERA Stock | USD 47.46 0.19 0.40% |
Long Term Debt To Capitalization | First Reported 2010-12-31 | Previous Quarter 0.32908645 | Current Value 0.17 | Quarterly Volatility 0.08098603 |
Check Vera Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Vera Therapeutics' main balance sheet or income statement drivers, such as Tax Provision of 800, Net Interest Income of 3.8 M or Interest Income of 7.3 M, as well as many indicators such as Price To Sales Ratio of 282, Dividend Yield of 0.0 or PTB Ratio of 6.78. Vera financial statements analysis is a perfect complement when working with Vera Therapeutics Valuation or Volatility modules.
Vera | Long Term Debt To Capitalization |
Latest Vera Therapeutics' Long Term Debt To Capitalization Growth Pattern
Below is the plot of the Long Term Debt To Capitalization of Vera Therapeutics over the last few years. It is Vera Therapeutics' Long Term Debt To Capitalization historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Vera Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Long Term Debt To Capitalization | 10 Years Trend |
|
Long Term Debt To Capitalization |
| Timeline |
Vera Long Term Debt To Capitalization Regression Statistics
| Arithmetic Mean | 0.10 | |
| Geometric Mean | 0.09 | |
| Coefficient Of Variation | 79.10 | |
| Mean Deviation | 0.06 | |
| Median | 0.07 | |
| Standard Deviation | 0.08 | |
| Sample Variance | 0.01 | |
| Range | 0.263 | |
| R-Value | 0.63 | |
| Mean Square Error | 0 | |
| R-Squared | 0.40 | |
| Significance | 0.01 | |
| Slope | 0.01 | |
| Total Sum of Squares | 0.09 |
Vera Long Term Debt To Capitalization History
About Vera Therapeutics Financial Statements
Vera Therapeutics stakeholders use historical fundamental indicators, such as Vera Therapeutics' Long Term Debt To Capitalization, to determine how well the company is positioned to perform in the future. Although Vera Therapeutics investors may analyze each financial statement separately, they are all interrelated. For example, changes in Vera Therapeutics' assets and liabilities are reflected in the revenues and expenses on Vera Therapeutics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Vera Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Long Term Debt To Capitalization | 0.33 | 0.17 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Vera Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Vera Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Vera Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Vera Therapeutics Stock:Check out the analysis of Vera Therapeutics Correlation against competitors. For information on how to trade Vera Stock refer to our How to Trade Vera Stock guide.You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Vera Therapeutics. If investors know Vera will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Vera Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.61) | Return On Assets (0.33) | Return On Equity (0.65) |
The market value of Vera Therapeutics is measured differently than its book value, which is the value of Vera that is recorded on the company's balance sheet. Investors also form their own opinion of Vera Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Vera Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Vera Therapeutics' market value can be influenced by many factors that don't directly affect Vera Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Vera Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Vera Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Vera Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.